0.01
—
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Navco Pharmaceuticals
Its shares trade on TSX Venture under the ticker NAV.V. It has been listed since 5 November 2018.
Navco Pharmaceuticals, Inc. engages in the manufacture, research, and development of nanotechnology products to protect against viruses, bacteria and infectious diseases. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2018-11-05. The firm is engaged in developing and commercializing products to protect against viruses, bacteria, and infectious diseases. The company manufactures and researches nanotechnology products and materials using Computerized Nano-meter Algorithms (CNA). The firm's pipeline of applications is tailored to defend against microorganisms such as viruses, bacteria, fungi, and genetic manipulation tools such as clustered regularly interspaced short palindromic repeats (CRISPR). Its target markets include human health and personal skin care, household and institutional products and veterinary health. The company offers multiple main product lines, namely, an aerosol spray, hand sanitizer, hand cream, and nano BioGuard-Silver.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 5 Nov 2018
Leadership
Pay as last reported
- Mr. Geoffrey LeeChief Executive OfficerC$72,000
- Mr. Christopher CooperChief Financial OfficerC$31,500
- Mr. Marek JasinskiChief Operating Officer, Director, since 2023C$72,000
- Mr. Thomas JusdanisCorporate Secretary, Director, since 2013C$11,250
- Mr. Jatinder DhaliwalIndependent Director
- Ms. Judy SuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Navco's nanotechnology products protect against viruses, bacteria, and infectious diseases using CNA algorithms.
- The company's product lines include aerosol spray, hand sanitizer, and nano BioGuard-Silver for diverse markets.
- Navco's pipeline targets microorganisms like viruses, bacteria, fungi, and CRISPR tools for defense applications.
Weaknesses
- Navco's headquarters in Vancouver, British Columbia may limit global market access.
- The company's focus on nanotechnology products could face regulatory hurdles in different countries.
- Navco's reliance on CNA algorithms might create dependency on specific technological expertise.
Opportunities
- Expanding into veterinary health markets with nano BioGuard-Silver for animal care products.
- Growing demand for nanotechnology in household and institutional products for infection control.
- Increasing interest in CRISPR defense applications for genetic manipulation tools globally.
Threats
- Competition from established health care companies in the nanotechnology sector.
- Regulatory challenges in the Financials sector affecting product approvals.
- Potential market saturation in the Consumer Discretionary segment for hand sanitizers.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.